---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-069206"
form_type: "8-K"
ticker: "RZLT"
cik: "0001509261"
company_name: "Rezolute, Inc."
filed_at: "2026-06-02T11:05:59+00:00"
generated_at: "2026-06-02T11:10:49.217306+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Rezolute reports positive interim Phase 3 upLIFT data: 6 of 8 patients met primary endpoint

## Summary
- 8 patients enrolled (50% of planned 16); 6 responders with ≥50% reduction in IV glucose, all 6 achieved complete discontinuation.
- One patient withdrew due to cancer progression (Stage 4 colon cancer) counted as non-responder; one patient recently enrolled and dosing.
- No drug-related adverse events; all completing pivotal phase entered open-label extension, cumulative treatment up to 6 months.
- Topline results for fully enrolled study expected in second half of 2026.
- Data supports ersodetug as potential universal treatment for refractory hypoglycemia from congenital and acquired hyperinsulinism.

## SEC filing metadata
- accession: 0001104659-26-069206
- form_type: 8-K
- ticker: RZLT
- cik: 0001509261
- company_name: Rezolute, Inc.
- filed_at: 2026-06-02T11:05:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/0001104659-26-069206-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1509261/000110465926069206/tm2616579d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-069206
- JSON: https://secwatch.observer/filing/0001104659-26-069206.json
- Plain text: https://secwatch.observer/filing/0001104659-26-069206.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.